Key Takeaways:
The United Laboratories International Holdings (HK:3933) won U.S. FDA approval to trial UBT48128, an oral GLP-1 drug for obesity and type 2 diabetes.
The approval, granted to wholly owned unit The United Bio-Technology (Hengqin) Co., Ltd., covers an Investigational New Drug application for the Class 1 innovative drug, the company said in a filing. UBT48128 is a small-molecule glucagon-like peptide-1 receptor agonist that lowers blood glucose and reduces body weight by promoting insulin secretion while controlling appetite and regulating energy metabolism. The candidate reflects the group's strategic emphasis on innovative chronic-disease therapies.
Preclinical animal studies showed UBT48128 significantly reduced body weight and blood glucose, with weight-loss efficacy reported as superior to existing drugs in the same class, the company said. The group plans to advance development of the candidate and broaden its pipeline, a move that could strengthen its competitiveness in biopharmaceuticals if clinical results confirm the early findings.
The stock fell 0.27 percent, with a market capitalization of HK$18.19 billion. The most recent analyst rating is a Buy with a HK$20.00 price target. Short selling reached HK$9.90 million, a 20.9 percent ratio, as of Aug. 11.
The approval puts United Laboratories in the race for the oral GLP-1 market now dominated by Novo Nordisk and Eli Lilly, whose injectable weight-loss drugs generated tens of billions in annual sales. Oral formulations are seen as the next frontier because they remove the injection barrier that limits patient adoption. A successful clinical program could open a share of that market and draw partnership interest from larger drugmakers.
The company, a Cayman Islands-incorporated pharmaceutical group, develops treatments for chronic diseases through subsidiaries including The United Bio-Technology (Hengqin). It earlier this year secured a Novo Nordisk milestone payment for its obesity candidate UBT251, deepening ties with the Danish drugmaker. The FDA clearance also gives the Hong Kong-listed group a foothold in the U.S. market, where Chinese drugmakers have historically struggled to gain regulatory traction.
United Laboratories has not yet scheduled first human-trial data for UBT48128, which will determine whether the preclinical weight-loss advantage holds in patients. Investors will watch for enrollment updates and any partnership announcements tied to the program.
This article is for informational purposes only and does not constitute investment advice.
